Determinants of long-term persistence with tiotropium bromide for chronic obstructive pulmonary disease

Kyuto Tanaka, Nobufumi Kamiishi, Jun Miyata, Hiroki Kabata, Katsunori Masaki, Hiromi Ogura-Tomomatsu, Katsuyoshi Tomomatsu, Yusuke Suzuki, Koichi Fukunaga, Koichi Sayama, Tomoko Betsuyaku, Koichiro Asano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Tiotropium bromide, a long-acting anticholinergic agent, improves pulmonary function and quality of life of patients suffering from chronic obstructive pulmonary disease (COPD). We retrospectively examined the factors that determine the long-term persistence with tiotropium bromide. Among 6,301 patients who underwent pulmonary function tests in our pulmonary clinic between 2006 and 2009, 644 met the following criteria: 1) age > 40 years, 2) ≥ 20 pack-years smoking history, and 3) forced expiratory volume in 1 sec/forced vital capacity ratio < 0.7. The clinical information, including the prescription of tiotropium, was obtained from the patients' records. Tiotropium was administered to 255 patients (40%), of whom 48 (19%) discontinued treatment within 1 year, and 65 (25%) discontinued treatment within the median observation period of 32 months. The drug was discontinued because of ineffectiveness in 35 patients (73%), and because of adverse drug effects in 13 patients (27%). Young age, current smoking, absence of respiratory symptoms alleviation, and less severe disease characterized by a) mild airflow limitation, b) mild to moderate emphysema, or c) no exacerbation of COPD during the 1<sup>st</sup> year of treatment were predictors of drug discontinuation.

Original languageEnglish
Pages (from-to)233-239
Number of pages7
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume12
Issue number3
DOIs
Publication statusPublished - 2015 May 4

Fingerprint

Chronic Obstructive Pulmonary Disease
Lung
Respiratory Function Tests
Vital Capacity
Forced Expiratory Volume
Cholinergic Antagonists
Smoking
History
Quality of Life
Pharmaceutical Preparations
Tiotropium Bromide
Therapeutics

Keywords

  • Anticholinergic therapy
  • Long-term therapy
  • Tachyphylaxis
  • Treatment effectiveness
  • Treatment tolerability

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Determinants of long-term persistence with tiotropium bromide for chronic obstructive pulmonary disease. / Tanaka, Kyuto; Kamiishi, Nobufumi; Miyata, Jun; Kabata, Hiroki; Masaki, Katsunori; Ogura-Tomomatsu, Hiromi; Tomomatsu, Katsuyoshi; Suzuki, Yusuke; Fukunaga, Koichi; Sayama, Koichi; Betsuyaku, Tomoko; Asano, Koichiro.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 12, No. 3, 04.05.2015, p. 233-239.

Research output: Contribution to journalArticle

Tanaka, Kyuto ; Kamiishi, Nobufumi ; Miyata, Jun ; Kabata, Hiroki ; Masaki, Katsunori ; Ogura-Tomomatsu, Hiromi ; Tomomatsu, Katsuyoshi ; Suzuki, Yusuke ; Fukunaga, Koichi ; Sayama, Koichi ; Betsuyaku, Tomoko ; Asano, Koichiro. / Determinants of long-term persistence with tiotropium bromide for chronic obstructive pulmonary disease. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2015 ; Vol. 12, No. 3. pp. 233-239.
@article{fa435e1ee1564a66990d65374ea55597,
title = "Determinants of long-term persistence with tiotropium bromide for chronic obstructive pulmonary disease",
abstract = "Tiotropium bromide, a long-acting anticholinergic agent, improves pulmonary function and quality of life of patients suffering from chronic obstructive pulmonary disease (COPD). We retrospectively examined the factors that determine the long-term persistence with tiotropium bromide. Among 6,301 patients who underwent pulmonary function tests in our pulmonary clinic between 2006 and 2009, 644 met the following criteria: 1) age > 40 years, 2) ≥ 20 pack-years smoking history, and 3) forced expiratory volume in 1 sec/forced vital capacity ratio < 0.7. The clinical information, including the prescription of tiotropium, was obtained from the patients' records. Tiotropium was administered to 255 patients (40{\%}), of whom 48 (19{\%}) discontinued treatment within 1 year, and 65 (25{\%}) discontinued treatment within the median observation period of 32 months. The drug was discontinued because of ineffectiveness in 35 patients (73{\%}), and because of adverse drug effects in 13 patients (27{\%}). Young age, current smoking, absence of respiratory symptoms alleviation, and less severe disease characterized by a) mild airflow limitation, b) mild to moderate emphysema, or c) no exacerbation of COPD during the 1st year of treatment were predictors of drug discontinuation.",
keywords = "Anticholinergic therapy, Long-term therapy, Tachyphylaxis, Treatment effectiveness, Treatment tolerability",
author = "Kyuto Tanaka and Nobufumi Kamiishi and Jun Miyata and Hiroki Kabata and Katsunori Masaki and Hiromi Ogura-Tomomatsu and Katsuyoshi Tomomatsu and Yusuke Suzuki and Koichi Fukunaga and Koichi Sayama and Tomoko Betsuyaku and Koichiro Asano",
year = "2015",
month = "5",
day = "4",
doi = "10.3109/15412555.2014.933795",
language = "English",
volume = "12",
pages = "233--239",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Determinants of long-term persistence with tiotropium bromide for chronic obstructive pulmonary disease

AU - Tanaka, Kyuto

AU - Kamiishi, Nobufumi

AU - Miyata, Jun

AU - Kabata, Hiroki

AU - Masaki, Katsunori

AU - Ogura-Tomomatsu, Hiromi

AU - Tomomatsu, Katsuyoshi

AU - Suzuki, Yusuke

AU - Fukunaga, Koichi

AU - Sayama, Koichi

AU - Betsuyaku, Tomoko

AU - Asano, Koichiro

PY - 2015/5/4

Y1 - 2015/5/4

N2 - Tiotropium bromide, a long-acting anticholinergic agent, improves pulmonary function and quality of life of patients suffering from chronic obstructive pulmonary disease (COPD). We retrospectively examined the factors that determine the long-term persistence with tiotropium bromide. Among 6,301 patients who underwent pulmonary function tests in our pulmonary clinic between 2006 and 2009, 644 met the following criteria: 1) age > 40 years, 2) ≥ 20 pack-years smoking history, and 3) forced expiratory volume in 1 sec/forced vital capacity ratio < 0.7. The clinical information, including the prescription of tiotropium, was obtained from the patients' records. Tiotropium was administered to 255 patients (40%), of whom 48 (19%) discontinued treatment within 1 year, and 65 (25%) discontinued treatment within the median observation period of 32 months. The drug was discontinued because of ineffectiveness in 35 patients (73%), and because of adverse drug effects in 13 patients (27%). Young age, current smoking, absence of respiratory symptoms alleviation, and less severe disease characterized by a) mild airflow limitation, b) mild to moderate emphysema, or c) no exacerbation of COPD during the 1st year of treatment were predictors of drug discontinuation.

AB - Tiotropium bromide, a long-acting anticholinergic agent, improves pulmonary function and quality of life of patients suffering from chronic obstructive pulmonary disease (COPD). We retrospectively examined the factors that determine the long-term persistence with tiotropium bromide. Among 6,301 patients who underwent pulmonary function tests in our pulmonary clinic between 2006 and 2009, 644 met the following criteria: 1) age > 40 years, 2) ≥ 20 pack-years smoking history, and 3) forced expiratory volume in 1 sec/forced vital capacity ratio < 0.7. The clinical information, including the prescription of tiotropium, was obtained from the patients' records. Tiotropium was administered to 255 patients (40%), of whom 48 (19%) discontinued treatment within 1 year, and 65 (25%) discontinued treatment within the median observation period of 32 months. The drug was discontinued because of ineffectiveness in 35 patients (73%), and because of adverse drug effects in 13 patients (27%). Young age, current smoking, absence of respiratory symptoms alleviation, and less severe disease characterized by a) mild airflow limitation, b) mild to moderate emphysema, or c) no exacerbation of COPD during the 1st year of treatment were predictors of drug discontinuation.

KW - Anticholinergic therapy

KW - Long-term therapy

KW - Tachyphylaxis

KW - Treatment effectiveness

KW - Treatment tolerability

UR - http://www.scopus.com/inward/record.url?scp=84933502524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933502524&partnerID=8YFLogxK

U2 - 10.3109/15412555.2014.933795

DO - 10.3109/15412555.2014.933795

M3 - Article

VL - 12

SP - 233

EP - 239

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 3

ER -